List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
Researchers in Brazil and Poland have developed an AI-powered tool that predicts cancer aggressiveness by analysing protein expression - offering new insights into tumour behaviour.
In the fight against antibiotic-resistant bacteria, researchers at Michigan State University (MSU) have made a discovery that could change how we target deadly pathogens like Staphylococcus aureus and its drug-resistant strain - MRSA.
Immune cells in the brain called microglia may hold the key to improving blood flow and tackling diseases like Alzheimer’s, new research from the University of Virginia suggests.
9 July 2025 | By Eurofins Discovery
Safety data is no longer just a regulatory checkbox - it’s a strategic advantage. Discover how in vitro and computational tools reduce the reliance on animal testing and support smarter, earlier decision-making in drug discovery.
A study from Weill Cornell Medicine shows that pre-treating pancreatic islet cells with a small molecule cocktail significantly improves survival after transplantation in type 1 diabetes models. The approach could help make donor cells go further and transplants more efficient.
A hormone produced in the gut, FGF19, has been shown to act directly on the brain to boost energy expenditure, burn fat and improve blood sugar control in obese mice - offering a potential route for developing new obesity therapies.
Japanese researchers have identified the epigenetic enzyme SETD1B as a key driver of aggressive acute myeloid leukaemia (AML) – which could lead to new treatment strategies targeting the cancer’s underlying biology in the future.
Scientists have developed a new AI-guided tool that predicts how bowel cancer becomes resistant to treatment – which could lead to development of new personalised therapies.
Researchers from UT Health San Antonio have identified the CST protein complex as a key driver of resistance to PARP inhibitors in BRCA1-deficient cancers – which could lead to more personalised treatments for breast, ovarian and prostate cancer patients.
Dr Justin Taylor of Sylvester Comprehensive Cancer Center has identified a promising drug combination that shrinks colorectal tumours in preclinical models.
Chiesi Group and Key2Brain have signed a global license agreement to develop two blood-brain barrier-crossing enzyme replacement therapies for alpha-mannosidosis and Krabbe disease – with the aim to help patients with limited treatment options.
James Atwood, COO of Opentrons, shares how accessible lab automation is helping research teams tackle tighter budgets, faster timelines and complex discovery workflows.
Researchers at the University of Alabama have identified reelin, a glycoprotein known for its role in brain development, as a key regulator of neurons in the brain's reward centre, potentially making way for targeted therapies against cocaine use.
An experimental peptide from Virginia Tech may offer a new way to stop glioblastoma from coming back by disrupting the cancer’s treatment-resistant core.
A new study from the University of Barcelona’s Institute of Neurosciences has discovered a crucial role for the RTP801 protein in astrocytes, potentially making way for future therapies aimed at slowing or reversing cognitive decline.
